APLIF - DSMB recommends continuing Appili's late-stage COVID-19 trial without modification

Appili Therapeutics (APLIF) announces that an independent Data and Safety Monitoring Board ((DSMB)) has recommended continuation without modification of the company's ongoing Phase 3 PRESECO COVID-19 trial.The study is evaluating the safety and efficacy of Avigan/Reeqonus, an oral antiviral that selectively inhibits viral RNA-dependent RNA polymerase ((RdRP)), as a potential treatment for patients with mild-to-moderate COVID-19.The primary goal of the study is to demonstrate a significant shortening of the time to sustained recovery for study patients receiving the experimental medicine compared to a placebo. The DSMB reported no safety issues that would have required the study to be terminated.Appili will continue recruiting patients at the 27 study sites across the United States and expects to report top-line results in Q3 2021.

For further details see:

DSMB recommends continuing Appili's late-stage COVID-19 trial without modification